首页|血行播散性肺结核耐药情况分析(附71例报告)

血行播散性肺结核耐药情况分析(附71例报告)

扫码查看
目的 分析血行播散性肺结核患者的耐药特点,为临床制定个体化治疗方案提供参考。方法 回顾性分析2015年1月-2024年1月首都医科大学附属北京胸科医院收治的71例血行播散性肺结核住院患者的临床资料。采用分枝杆菌微孔板药敏检测技术检测来自71例患者的结核分枝杆菌对16种抗结核药的敏感性,分析血行播散性肺结核患者的结核分枝杆菌培养结果、药敏试验结果、初治或复治情况、耐药情况,以及初治与复治患者耐药类型的差异。结果 71例血行播散性肺结核患者中,男51例(71。8%),急性血行播散性肺结核58例(81。7%),对16种抗结核药的总耐药率为38。0%。复治患者总耐药率与初治患者比较差异无统计学意义[52。2%(12/23)vs。31。3%(15/48),P=0。089]。患者对16种抗结核药任一耐药的前7位为链霉素(Sm)、异烟肼(INH)各13例(18。3%),利福喷丁(Rft)、对氨基水杨酸异烟肼(Pa)各10例(14。1%),利福平(RFP)、利福布汀(Rfb)、卷曲霉素(Cm)各9例(12。7%);初治患者任一耐药的前6位为Cm 6例(12。5%),Sm 5例(10。4%),Pa 4例(8。3%),INH、克拉霉素(Clr)、对氨基水杨酸(PAS)各3例(6。3%);复治患者任一耐药的前7位为INH 10例(43。5%),Sm、RFP、Rft各8例(34。8%),Rfb 7例(30。4%),Pa、左氧左旋氧氟沙星(Lfx)各6例(26。1%)。患者对16种抗结核药的总单耐药率、总多耐药率、总耐多药率分别为9。9%、7。0%、11。3%;所有单耐药患者均为初治患者;复治患者多耐药率与初治患者比较差异无统计学意义[13。0%vs。4。2%,P=0。591],但耐多药率明显高于初治患者[30。4%vs。2。1%,P=0。002]。结论 血行播散性肺结核耐药情况严峻,临床医师可根据药敏试验结果制定个性化的抗结核治疗方案。
Analysis of drug resistance in disseminated pulmonary tuberculosis:71 cases report
Objective To analyze the characteristics of drug resistance in patients with disseminated pulmonary tuberculosis,and provide references for the clinical development of individualized treatment plans.Methods A retrospective analysis was conducted on 71 hospitalized patients with disseminated pulmonary tuberculosis treated at the Beijing Chest Hospital,Capital Medical University from January 2015 to January 2024.The susceptibility of Mycobacterium tuberculosis from these patients to 16 anti-tuberculosis drugs was detected using the microplate method for mycobacterial drug susceptibility testing.The study analyzed the culture results of Mycobacterium tuberculosis,drug susceptibility test results,initial treatment or re-treatment status,drug resistance,and differences in drug resistance types between initial and re-treated patients.Results Among the 71 patients with disseminated pulmonary tuberculosis,there were 51 males(71.8%),and 58 cases(81.7%)of acute disseminated pulmonary tuberculosis,with an overall drug resistance rate to 16 anti-tuberculosis drugs of 38.0%.There was no statistically significant difference in the total drug resistance rate between re-treated patients and those undergoing initial treatment[52.2%(12/23)vs.31.3%(15/48),P=0.089].The top 7 drugs to which patients were resistant were streptomycin(Sm)and isoniazid(INH)with 13 cases each(18.3%),rifapentine(Rft)and isoniazid aminosalicylate(Pa)with 10 cases each(14.1%),rifampicin(RFP),rifabutin(Rfb),and capreomycin(Cm)with 9 cases each(12.7%).The top 6 drugs to which initially treated patients were resistant were Cm with 6 cases(12.5%),Sm with 5 cases(10.4%),Pa with 4 cases(8.3%),INH,clarithromycin(Clr),and p-aminosalicylic acid(PAS)with 3 cases each(6.3%).The top 7 drugs to which re-treated patients were resistant were INH with 10 cases(43.5%),Sm,RFP,and Rft with 8 cases each(34.8%),Rfb with 7 cases(30.4%),Pa and levofloxacin(Lfx)with 6 cases each(26.1%).The overall mono-resistance rate,poly-drug resistance rate,and multidrug-resistant rate to 16 anti-tuberculosis drugs were 9.9%,7.0%,and 11.3%,respectively;all mono-resistance patients were initially treated;there was no statistically significant difference in the poly-drug resistance rate between re-treated and initially treated patients(13.0%vs.4.2%,P=0.591),but the multidrug-resistant rate was significantly higher in re-treated patients(30.4%vs.2.1%,P=0.002).Conclusion Drug resistance in disseminated pulmonary tuberculosis is severe.Clinical physicians can develop personalized anti-tuberculosis treatment plans based on drug susceptibility test results.

disseminated pulmonary tuberculosisantimicrobial susceptibility testdrug resistancemulti-drug resistance

施亦衡、王潮虹、杨斌、孙晴、晏君、龙嗣博、郑迈克、赵艳、王桂荣

展开 >

北京市结核病胸部肿瘤研究所/首都医科大学附属北京胸科医院检验科,北京 101149

血行播散性肺结核 药物敏感性试验 耐药性 耐多药

2024

解放军医学杂志
人民军医出版社

解放军医学杂志

CSTPCD北大核心
影响因子:1.644
ISSN:0577-7402
年,卷(期):2024.49(12)